Akero Therapeutics’ Post

Ophthopedia Update:Glycemic Trends in Thyroid Eye Disease (TED) Patients Treated with Teprotumumab in 3 Clinical Trials: Assess incidence, severity, and outcomes of serum glucose excursions in patients with thyroid eye disease who received the insulin-like growth factor-1 receptor inhibitor, teprotumumab, during pivotal clinical trials. #Ophthalmology #ophthotwitter #eyecare

https://lnkd.in/gRvgShRS Genentech presents the optimization of TRPA1 antagonists with robust in vivo engagement, offering the potential for neuropathic pain and respiratory disease treatment. Initial lead molecules displayed coagulation parameter prolongation, attributed to an AO-generated metabolite akin to known anticoagulants. Further compound refinement mitigated coagulation effects, leading to clinical candidate GDC-6599, currently in Phase II trials for respiratory indications.

The HERCULES phase 3 trial spotlights tolebrutinib's potential as a transformative therapy for non-relapsing secondary progressive multiple sclerosis (nrSPMS), particularly given the significant unmet need in this patient population. Its ability to delay disability progression by 31% not only underscores the efficacy of this brain-penetrant BTK inhibitor but also paves the way for more innovative treatment strategies targeting progressive disease mechanisms. The parallel results from the GEMINI studies suggest that, while traditional relapse metrics may not fully capture the benefits of tolebrutinib, the drug still shows promise in addressing neuroinflammation—a crucial factor in disease progression. Going forward, the thorough examination of safety data, including the observed liver enzyme elevations, will be essential as regulatory submissions approach in the latter half of 2024, setting the stage for what could be a significant advancement in multiple sclerosis treatment. For additional information, click here: https://rb.gy/l6pdlh.

Today is World Sickle Cell Day 2024 Sickle Cell Disease * Sickle Cell Disease (SCD) is a rare inherited disorder that affects red blood cells. * Pain is the leading cause of hospitalization. The hallmark of SCD are these acute pain crises called vaso-occlusion that are a result of not enough oxygen reaching tissues and organs. * It is a serious and lifelong condition, and people with SCD experience many health problems. Afimmune are now enrolling for Sickle Cell Study to assess the effectiveness of Epeleuton, a novel treatment for Sickle Cell Disease. Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a next-generation synthetic small molecule drug. Epeleuton is a potential novel therapeutic option (NCE) for clinical management of patients with Sickle Cell Disease that targets multiple aspects of the disease. Visit https://lnkd.in/eBwrP6wy for more info on how to get involved. #WorldSickleCellDay #SickleCellDisease #Epeleuton #Afimmune

How do we streamline cytomegalovirus (CMV) prevention in hematopoietic cell transplant (HCT) recipients? Check out this educational program to discover insights on navigating CMV risk factors and prophylaxis in HCT. This program provides guidance on identifying patients at high risk for CMV reactivation and the strategic use of prophylactic versus preemptive therapy. You'll discover a comprehensive analysis of the latest treatment modalities, including cutting-edge antiviral therapies poised to fill existing care gaps. Gain a deeper understanding of how donor and recipient serostatus influences risk and treatment decisions and learn to tailor care to meet the unique needs of each HCT recipient. Enhance your practice today: https://ow.ly/80AY50QGcHc #NursePractitioners #InfectiousDiseases #CMVManagement

Hepatic stellate cells (HSCs) are a type of 'minority' cell in the liver, but serve critical functions in a healthy liver and in response to injury. When there's an injury to the Liver, these HSCs activate to produce 'scar tissue' in liver fibrosis. Our publication below explains the co-culture we created to 'mimic' the effects liver scarring and develop better therapeutics for this disease. https://lnkd.in/gZjr-R_x

More than 40% of IBD patients fail to respond to therapy. This is a major problem, as IBD can be a debilitating disease. There is an unmet need for high-quality human data to help drug developers identify effective IBD therapies. We understand that most physiologically-relevant and human-derived systems are not cost effective, take time and are not reproducible. Acknowledging this we have developed IntegriGut Screen Efficacy - a rapid, reprodcible and physiologically relevant screening platform based on patient-derived organoids. Are you interested in learning more about IntegriGut Screen Efficacy? Click on the link below to learn more. #patientinthelab #organoids #IBD #inflammation #inflammatoryboweldisease #guthealth #digestivedisease

Among patients with polyarticular-course juvenile idiopathic arthritis who started receiving a second biologic, there is no difference in achievement of inactive disease or minimal disease activity at six months between receiving a second second tumor necrosis factor inhibitor (TNFi) versus a non-TNFi biologic. The most common biological treatment scheme in these patients is to use #etanercept as the first biological (84%), and after discontinuation of receiving a first TNFi to switch to a second TNFi (85%), usually #adalimumab, rather than change to a different class of biologic. 🔗https://lnkd.in/dVGcN8FF

When we will be able to reverse atherosclerosis? Brilliant as ever talk by Matthew O'Connor Not all cholesterol is bad, but let’s talk about 7KC – it’s the real villain here. Macrophages can’t “clean” it from blood vessel walls, so they turn into foam cells. Cyclodextrins, a class of compounds, have the potential to “cleanse” cholesterol, but they also come with toxicity concerns. Cyclarity Therapeutics is doing groundbreaking work in modifying this class of compounds, and the drugs they’re developing could truly revolutionize the treatment of cardiovascular diseases. Their lead compound, UDP-003, has the ability to prevent changes caused by 7KC at a molecular level, essentially reversing atherosclerotic changes reversing existing plaques! This year, the company is kicking off clinical trials involving 72 healthy volunteers and 12 patients post cardiac events. Phase 2 trials are slated for the end of 2027. #aging #CVD #cholesterol

September 15 is the International #MyotonicDystrophyAwarenessDay! #MyotonicDystrophy is the most common form of #musculardystrophies, a group of #rare #neuromuscular diseases that cause progressive weakness and degeneration of skeletal muscles. Our team at GrittGene Therapeutics, is committed to bringing effective solutions for those affected by Myotonic Dystrophy Type 2 (#DM2) in the form of innovative treatments and a robust and precise diagnostic tool. If you or a loved one is living with DM2, let’s connect for our shared mission to win over Myotonic Dystrophy Type 2.   #MyotonicDystrophyType2 #GrittGeneTherapeutics #MuscularDystrophy #RareDisease #NeuromuscularDisorders #MyotonicDystrophy #GeneTherapy #CellTherapy #StemCellTherapy Myotonic Dystrophy Foundation